

study, we reviewed the clinical features of patients who developed HCC after undergoing HCV eradication. Although the risk factors for hepatocarcinogenesis were not statistically analyzed due to the lack of data for non-HCC patients with an SVR, the characteristics of a relatively large number of patients may provide general information regarding the clinical features and present state of patients who develop HCC after obtaining an SVR in Japan.

At the time of HCC diagnosis, 117 patients had one or two tumors, and the tumor size was ≤ 3 cm in 102 patients. A total of 110 patients received curative therapy, suggesting that SVR patients are receiving appropriate follow-up care (23) in most of the hospitals that participated in this study.

A majority of the patients were men, received IFN treatment at an older age and had an advanced stage of liver fibrosis, as previously reported (15-21). A considerable number of patients had a background of alcohol intake, obesity and diabetes mellitus prior to IFN treatment, irrespective of the stage of liver fibrosis. These background characteristics have synergistic effects on hepatocarcinogenesis in chronic HCV patients (24-27). Some studies have suggested that alcohol intake is also a risk factor for HCC development among SVR patients (16, 17). Arase et al. (28) recently reported that both alcohol intake and diabetes increase the risk of HCC development in SVR patients without cirrhosis and non-SVR patients with cirrhosis, consistent with the findings of this study. To clarify the associations between these factors, including obesity, prospective cohort studies involving a large number of patients and data on the clinical features of patients who have undergone HCV eradication and individuals with a relatively low volume of alcohol intake, especially female patients, are needed.

An advanced age at HCV eradication is considered to be a risk factor for HCC development in SVR patients (15-21, 29), and most patients in this study were >50 years when they received IFN therapy. Although 16 patients received IFN therapy before 50 years of age, 12 had advanced fibrosis with cirrhosis or a lower platelet count, and three patients were heavy alcohol drinkers before IFN treatment. The number of heavy alcohol drinkers in this group was higher than that of male patients >50 years old (56.3% versus 29.7%, $p=0.038$), which suggests that alcohol intake may influence hepatocarcinogenesis and the progression of liver fibrosis in this group.

Nagaoki et al. (30) reported an older age at HCV eradication and heavy alcohol intake as risk factors for HCC development within five years of HCV eradication. In this study, an older age at IFN treatment initiation tended to be associated with an increased risk of HCC, and the development of HCC within five years was significantly associated with lower albumin and higher AFP levels at IFN treatment initiation. Kurosaki et al. (31) reported lower albumin levels as one risk factor for HCC development within five years among non-SVR patients without cirrhosis. However, it is uncertain as to why lower albumin levels are correlated with

the occurrence of HCC. Regarding the AFP level, Asahina et al. (32) recently reported that the posttreatment AFP level (≥ 6 ng/mL) is correlated with the development of HCC among IFN-treated patients; however, this is not the case with the pretreatment AFP level. This suggests that patients with a posttreatment AFP level of ≥ 6 ng/mL have a substantial risk of developing HCC and that, of these patients, those with a pretreatment AFP level of >10 ng/mL have a risk for early HCC development. Therefore, patients with these characteristics should be closely followed up during and after IFN therapy.

In conclusion, our investigation revealed that most patients who develop HCC after obtaining an SVR are men with advanced fibrosis and that lower albumin and higher AFP levels before IFN treatment may increase the risk for HCC development within five years of HCV eradication. In contrast, the risk factors for HCC development after 10 years of IFN treatment are uncertain, and such patients are not rare; therefore, all patients with chronic HCV should receive long-term follow-up care to monitor for the possible development of HCC following HCV eradication.

The authors state that they have no Conflict of Interest (COI).

Ethical Considerations

This study was approved by the Medical Ethics Committee of the St. Marianna University School of Medicine. The investigation conformed to the principles outlined in the Declaration of Helsinki.

References

1. World Health Organization. Global Alert and Response (GAR): Hepatitis C. 2012. Accessed 27 May 2013. <http://www.who.int/mediacentre/factsheets/fs164/en/index.html>
2. Center for Cancer Control and Information Services, National Cancer Center, Japan. Cancer Statistics in Japan-2011. Accessed 27 May 2013. http://ganjoho.jp/pro/statistics/en/backnumber/2012_en.html
3. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. *Hepato Res* 37: S95-S100, 2007.
4. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. *Ann Intern Med* 131: 174-181, 1999.
5. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. *J Hepatol* 28: 930-938, 1998.
6. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. *Hepatology* 18: 47-53, 1993.
7. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut* 47: 131-136, 2000.
8. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C: a long term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology* 29: 1124-1130, 1999.

9. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon- α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *Hepatology* **45**: 579-587, 2007.
10. Watanabe S, Enomoto N, Koike K, et al. Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. *Hepatol Res* **41**: 955-964, 2011.
11. Mashitani T, Yoshiji H, Yamazaki M, et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. *Cases J* **2**: 18, 2009.
12. Saito M, Seo Y, Yano Y, et al. Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review. *Clin J Gastroenterol* **5**: 119-126, 2012.
13. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. *J Gastroenterol* **31**: 552-558, 1996.
14. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. *Osaka Liver Disease Study Group. Hepatology* **27**: 1394-1402, 1998.
15. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. *Cancer* **101**: 1616-1622, 2004.
16. Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virological response to interferon therapy. *Liver Int* **24**: 603-610, 2004.
17. Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. *J Gastroenterol Hepatol* **20**: 752-758, 2005.
18. Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. *J Gastroenterol* **40**: 148-156, 2005.
19. Tanaka A, Uegaki S, Kurihara H, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. *World J Gastroenterol* **13**: 5180-5187, 2007.
20. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int* **27**: 186-191, 2007.
21. Hirakawa M, Ikeda K, Arase Y, et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. *Intern Med* **47**: 1637-1643, 2008.
22. The Examination Committee of Criteria for 'Obesity Disease' in Japan. Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. *Circ J* **66**: 987-992, 2002.
23. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2009 update. *Hepatol Res* **40** (Suppl 1): S2-S144, 2010.
24. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. *Gastroenterology* **127** (Suppl 1): S87-S96, 2004.
25. Ohishi W, Fujisawa S, Cologne JB, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. *Cancer Epidemiol Biomarkers Prev* **17**: 846-854, 2008.
26. Ohki T, Tateishi R, Sato T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. *Clin Gastroenterol Hepatol* **6**: 459-464, 2008.
27. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. *Gastroenterology* **135**: 111-121, 2008.
28. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. *Hepatology* **57**: 964-973, 2013.
29. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. *Hepatology* **52**: 518-527, 2010.
30. Nagaoki Y, Aikata H, Miyaki D, et al. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. *J Gastroenterol* **46**: 799-808, 2011.
31. Kurosaki M, Hiramatsu N, Sakamoto M, et al. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. *J Hepatol* **56**: 602-608, 2012.
32. Asahina Y, Tsuchiya K, Nishimura T, et al. α -fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. *Hepatology* **58**: 1253-1262, 2013.

α -Fetoprotein Levels After Interferon Therapy and Risk of Hepatocarcinogenesis in Chronic Hepatitis C

Yasuhiro Asahina,¹⁻³ Kaoru Tsuchiya,¹ Takashi Nishimura,^{1,4} Masaru Muraoka,^{1,5} Yuichiro Suzuki,^{1,5} Nobuharu Tamaki,¹ Yutaka Yasui,¹ Takanori Hosokawa,¹ Ken Ueda,¹ Hiroyuki Nakanishi,¹ Jun Itakura,¹ Yuka Takahashi,¹ Masayuki Kurosaki,¹ Nobuyuki Enomoto,⁵ Mina Nakagawa,² Sei Kakinuma,^{2,3} Mamoru Watanabe,² and Namiki Izumi¹

The effects of interferon (IFN) treatment and the post-IFN treatment α -fetoprotein (AFP) levels on risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC) are unknown. To determine the relationship between AFP and alanine transaminase (ALT) levels and HCC risk, a cohort consisting of 1,818 patients histologically proven to have CHC treated with IFN were studied. Cumulative incidence and HCC risk were analyzed over a mean follow-up period of 6.1 years using the Kaplan-Meier method and Cox proportional hazard analysis. HCC developed in 179 study subjects. According to multivariate analysis, older age, male gender, advanced fibrosis, severe steatosis, lower serum albumin levels, nonsustained virological response (non-SVR), and higher post-IFN treatment ALT or AFP levels were identified as independent factors significantly associated with HCC development. Cutoff values for ALT and AFP for prediction of future HCC were determined as 40 IU/L and 6.0 ng/mL, respectively, and negative predictive values of these cutoffs were high at 0.960 in each value. The cumulative incidence of HCC was significantly lower in patients whose post-IFN treatment ALT and AFP levels were suppressed to less than the cutoff values even in non-SVR patients. This suppressive effect was also found in patients whose post-IFN treatment ALT and AFP levels were reduced to less than the cutoff values despite abnormal pre-treatment levels. **Conclusion:** Post-IFN treatment ALT and AFP levels are significantly associated with hepatocarcinogenesis. Measurement of these values is useful for predicting future HCC risk after IFN treatment. Suppression of these values after IFN therapy reduces HCC risk even in patients without HCV eradication. (HEPATOLOGY 2013;58:1253-1262)

Hepatocellular carcinoma (HCC), one of the most frequent primary liver cancers,^{1,2} is the third most common cause of cancer mortality worldwide.³ Hepatitis C virus (HCV) infection is a common cause of chronic hepatitis, which progresses to HCC in many patients.⁴ In the last two decades, interferon (IFN) therapy has been used to treat chronic hepatitis C (CHC) with the goal of altering

the natural history of this disease. Although HCV eradication with IFN therapy for CHC has been shown to prevent HCC,⁵⁻⁹ HCC sometimes develops even after achieving viral eradication.⁵ Because the number of sustained virological responders (SVRs) is increasing along with recent advances in the development of effective anti-HCV therapy, it is very important to determine factors responsible for HCC

Abbreviations: AFP, α -fetoprotein; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; CHC, chronic hepatitis C; CT, computed tomography; γ -GTP, gamma-glutamyl transpeptidase; HCC, hepatocellular carcinoma; HCV, Hepatitis C virus; IFN, interferon; MRI, magnetic resonance imaging; PEG-, pegylated; RBV, ribavirin; ROC, receiver operator characteristic; SVR, sustained virological response.

From the ¹Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan; ²Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan; ³Department of Liver Disease Control, Tokyo Medical and Dental University, Tokyo, Japan; ⁴Department of Gastroenterology, Faculty of Medicine, Shiga University of Medical Science, Shiga, Japan; ⁵First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Received February 19, 2013; accepted April 4, 2013.

Supported by grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, and the Japanese Ministry of Welfare, Health, and Labor.

development among IFN-treated patients. However, this information is difficult to determine because of the paucity of large-scale, long-term cohort studies.

The 70-kDa glycoprotein α -fetoprotein (AFP), encoded by a gene located on chromosome 4, is the major serum protein during fetal life.¹⁰ Shortly before birth, AFP is replaced by albumin as the major serum protein,^{11,12} and thereafter, serum AFP levels remain extremely low throughout life (<10 ng/mL). Because serum AFP levels are frequently elevated in patients with HCC and germ-cell tumors, measurement of AFP is widely used as a serological marker for these tumors.^{8,13} However, AFP levels are sometimes elevated in patients with chronic viral hepatitis and cirrhosis who do not have HCC.^{3,19} While one possible explanation for this elevation is liver inflammation, in patients with CHC, the relationship between AFP and markers of liver inflammation such as alanine aminotransferase (ALT) is unclear. Moreover, although several reports suggest that pre-IFN treatment ALT and AFP levels in patients or those in patients who did not undergo subsequent treatment are associated with the development of HCC, it is unclear whether post-IFN treatment ALT and AFP levels are associated with hepatocarcinogenesis in patients with CHC. Hence, to clarify these associations we conducted a large-scale, long-term cohort study of patients with CHC to analyze the influence of ALT and AFP levels before and after IFN therapy on hepatocarcinogenesis in addition to other host and virological factors.

Patients and Methods

Patients. Patients chronically infected with HCV who had histologically proven chronic hepatitis or cirrhosis and had undergone IFN treatment between 1992 and 2010 were enrolled in the cohort. HCC was definitively ruled out by ultrasonography, dynamic computed tomography (CT), and/or magnetic resonance imaging (MRI) on enrollment. Patients were excluded if they had a history of HCC at the time of liver biopsy, autoimmune hepatitis, primary biliary cirrhosis, excessive alcohol consumption (≥ 50 g/day), hepatitis B surface antigen, or antihuman immunodeficiency virus antibody.

Based on these criteria, a total of 2,689 patients were initially enrolled. Of these, 223 (8.3%) patients were excluded from the cohort because of loss to follow-up. In the remaining 2,466 patients, 133 and 515 patients were excluded from this analysis because of short follow-up and retreatment with IFN-based therapy during the follow-up period, respectively. Thus, the cohort comprising 1,818 patients was analyzed in the present study. Written informed consent was obtained from all patients and the Ethical Committee of Musashino Red Cross Hospital approved this study, which was conducted in accordance with the Declaration of Helsinki.

Histological Evaluation. To obtain liver specimens, laparoscopic or ultrasound-guided liver biopsies were performed with 13G or 15G needles, respectively. The median length of specimen was 18 mm (range, 11–41 mm), and the mean number of portal tracts was 17 (range, 9–35). The stage of fibrosis and the grade of inflammatory activity were scored by two pathologists according to the classification of Desmet et al.²⁴ The percentage of steatosis was quantified by determining the average proportion of hepatocytes affected.

IFN Therapy and Definitions of Response to IFN Therapy. All patients had chronic HCV infection at liver biopsy, which was confirmed by the presence of HCV-RNA in serum. All IFN therapies were initiated within 48 weeks after liver biopsy. Among the 1,818 patients, 535 received IFN α or IFN β monotherapy for 24 weeks, 244 patients received IFN α ribavirin (RBV) combination therapy for 24 weeks, 299 patients received pegylated (PEG-) IFN α monotherapy for 48 weeks, and 760 patients received PEG-IFN α RBV combination therapy for 48–72 weeks.

Patients negative for serum HCV-RNA 24 weeks after IFN therapy completion were defined as SVRs. Patients who remained positive for HCV-RNA 24 weeks after therapy completion were defined as non-SVRs. HCV-RNA was determined by the qualitative Amplicor or TaqMan HCV assay (Roche Molecular Diagnostics, Tokyo, Japan).

Data Collection and Patient Follow-up. At enrollment, patient characteristics, biochemical,

Address reprint requests to: Yasuhiro Asahina, M.D., Ph.D., Professor, Department of Liver Disease Control, Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail: asahina.gast@tmd.ac.jp; fax: +81-3-5803-0268.

Copyright © 2013 by the American Association for the Study of Liver Diseases.

View this article online at wileyonlinelibrary.com.

DOI 10.1002/hep.26442

Potential conflict of interest: Dr. Asahina is on the speakers' bureau of Chugai Pharma and MSD, and received research funding from Daiichi-Sankyo and Chugai Pharma. Dr. Asahina and Dr. Kakinuma belong to a donation-funded department funded by Chugai Pharma, Toray, Bristol-Myers Squibb, Daiinippon-Sumitomo Pharma, and MSD.

Additional Supporting Information may be found in the online version of this article.

Table 1. Characteristics of Patients Enrolled in the Present Study

Factors	Value
Patients, n	1818
Sex, n (%)	
Male	833 (45.8)
Female	985 (54.2)
Age (SD), year	57.1 (12.0)
BMI (SD), kg/m ²	23.1 (3.2)
Fibrosis stage, n (%)	
F1/2	1384 (76.1)
F3/4	434 (23.9)
Activity grade, n (%)	
A0/1	964 (53.0)
A2/3	854 (47.0)
%Severe steatosis (≥10%)	23.7
Albumin (SD), g/dL	4.0 (0.38)
ALT (SD), IU/L	78.3 (71.0)
γ-GTP (SD), IU/L	49.8 (50.6)
T. Bilirubin (SD), mg/dL	0.73 (0.34)
Fasting blood sugar (SD), mg/dL	113.4 (37.8)
LDL-Cholesterol (SD), mg/dL	101.6 (28.9)
T. Cholesterol (SD), mg/dL	176.2 (38.4)
AFP (SD), ng/mL	11.3 (28.3)
WBC counts (SD),/μL	4990 (1516)
Hb (SD), g/dL	14.0 (1.7)
Platelet counts (SD), x10 ³ /μL	164 (54)
HCV load (SD), KU/mL	1097 (1263)
HCV genotype, n (%) [*]	
1a	11 (0.56)
1b	1183 (67.4)
2a	361 (20.6)
2b	180 (10.3)
Others	20 (1.1)
%Core 70 a.a. mutation [†]	34.2
%ISDR wild or 1 mutation [‡]	63.9
IFN regimen, n (%)	
IFN mono	758 (35.0)
IFN + RBV	275 (12.7)
PEG-IFN mono	307 (14.2)
PEG-IFN + RBV	758 (38.2)

Unless otherwise indicated, data are given as mean (SD).

^{*}HCV genotype was determined in 1755 patients.

[†]HCV core mutation was determined in 409 patients with genotype 1b.

[‡]ISDR was determined in 1264 patients with genotype 1b.

Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; LDL, low-density lipoprotein; AFP, α-fetoprotein; WBC, white blood cell; Hb, hemoglobin; HCV, hepatitis C virus; ISDR, interferon sensitivity determining region; IFN, interferon; RBV, ribavirin; PEG, pegylated.

hematological, virological, and histological data were collected. Age was determined at the time of primary liver biopsy. Patients were examined for HCC by abdominal ultrasonography, dynamic CT, and/or MRI every 3-6 months. Serum ALT and AFP levels were measured every 1-6 months. The surveillance protocols were in accordance with the standard of care in Japan. If HCC was suspected on the basis of the screening examination, additional procedures (e.g., dynamic CT, dynamic MRI, CT during hepatic arteriography, CT during arterial portography, contrast-enhanced ultrasonography, and tumor

biopsy) were used to confirm the diagnosis. HCC diagnosis was confirmed by needle biopsy, histology of surgically resected specimens, or characteristic radiological findings. To evaluate the effects of changes in serum ALT and AFP levels during IFN therapy on hepatocarcinogenesis, the average integration values of ALT and AFP in each patient were calculated before and after IFN therapy. Data obtained more than 1 year prior to HCC development were used to exclude AFP elevation caused by HCC itself.

Follow-up was between the date of primary liver biopsy and HCC development or the last medical attendance until June 2011. The mean follow-up period was 6.1 years (range, 1.0-20.8 years).

Statistical Analyses. Categorical data were compared by the chi-square test or Fisher's exact test. Distributions of continuous variables were analyzed with Student *t* test for two groups. All tests of significance were two-tailed and *P* < 0.05 was considered statistically significant. The cumulative incidence curve was determined by the Kaplan-Meier method, and differences among groups were assessed using the log-rank test. Factors associated with HCC risk were determined by the Cox proportional hazard model. As covariates in the multivariate stepwise Cox model, age, sex, stage of liver fibrosis, grade of histological activity, presence of hepatic steatosis, serum albumin levels, γ-glutamyl transpeptidase (γ-GTP) level, fasting blood sugar levels, platelet counts, pre-IFN ALT levels, pre-IFN AFP levels, post-IFN ALT levels, post-IFN AFP levels, and virological response were included. HCC development was the dependent variable. Time zero was defined as the time of primary liver biopsy. The proportional assumption was supported by log[-log(survival)] versus log(time) plots that showed parallel lines. Statistical analyses were performed using the Statistical Package for the Social Sciences software v. 18.0 (SPSS, Chicago, IL).

Results

Patient Characteristics and Factors Associated With Risk of HCC. Table 1 shows patient characteristics at the time of enrollment. During follow-up, HCC developed in 179 patients. The cumulative incidence of HCC for 5 and 10 years was 6.5% and 15.0%, respectively. The final virological response to IFN therapy was determined in all patients. The overall rate of SVRs was 50.2% (913/1818). The cumulative incidence in SVRs was 2.3% and 5.5%, respectively, which was significantly lower than that in non-SVRs (6.9% and 21.9%, respectively; log-rank test, *P* < 0.0001).

Univariate analysis demonstrated factors that increase the risk for HCC development (Table 2). According to

multivariate stepwise Cox analysis, older age, male gender, advanced fibrosis, severe steatosis, lower serum albumin levels, non-SVR, and higher post-IFN treatment ALT and AFP levels, but not pre-IFN treatment ALT and AFP levels, were identified as independent factors that were significantly associated with HCC development (Table 2).

Association of Post-IFN Treatment ALT and AFP Levels With HCC Development in SVRs and Non-SVRs. Because our multivariate analysis identified post-IFN treatment ALT and AFP levels as independent factors associated with HCC risk, we determined the cutoff values of these factors for predicting the development of HCC by receiver operator characteristics (ROC) analysis. The area under the ROC curve for post-IFN treatment ALT and AFP levels were higher than that for pre-IFN treatment ALT and AFP levels, suggesting that quantification of post-IFN treatment ALT and AFP levels rather than pre-IFN treatment levels of these values is useful for predicting HCC (Fig. 1A). From this ROC analysis, ALT <40 IU/L and AFP <6.0 ng/mL were identified as cutoff values. Negative predictive values were extremely high at 0.960 in each value, suggesting patients with ALT and/or AFP levels below these cutoff values are at a lower risk for HCC.

As shown in Fig. 1B, the hazard ratio determined by Cox proportional hazard analysis after adjustment for age, sex, stage of liver fibrosis, degree of liver steatosis, serum albumin levels, and virological response to therapy demonstrated that the hazard ratio for HCC was dependent on post-IFN treatment ALT and AFP levels. These hazard ratios increased predominantly when post-IFN treatment ALT and AFP levels were more than the cutoff values.

As shown in Fig. 2, the cumulative incidence of HCC was closely related to post-IFN treatment ALT and AST levels and was significantly lower in patients whose post-IFN treatment ALT and AFP levels was suppressed to <40 IU/L and 6.0 ng/mL, respectively. This suppressive effect was also notable in non-SVRs (Fig. 2C,D). Moreover, the cumulative incidence of HCC was significantly higher even in SVRs whose post-IFN treatment ALT and AFP levels were not <40 IU/L and 10 ng/mL, respectively (Fig. 2E,F).

Changes in ALT and AFP Levels With IFN Therapy and HCC Development. In the entire cohort, the mean ALT and AFP levels significantly decreased after IFN therapy (ALT = 78.4 to 36.6 IU/L, 95% confidence interval [CI] = 38.6-45.0, $P < 0.0001$; AFP = 11.3 to 6.9 ng/mL, 95% CI = 3.25-5.69, $P < 0.0001$; paired Student t test), and this significant

Table 2. Factors Associated With Hepatocellular Carcinoma

Risk Factor	Hazard Ratio (95% CI)	P Value
Univariate analysis		
Age (by every 10 year)	1.82 (1.52-2.20)	<0.0001
Sex		
Female	1	
Male	1.61 (1.20-2.17)	<0.0001
Fibrosis stage		
F1/F2	1	
F3/F4	4.90 (3.64-6.61)	<0.0001
Activity grade		
A0/A1	1	
A2/A3	3.38 (2.41-4.74)	<0.0001
Degree of steatosis		
<10%	1	
≥10%	3.84 (2.62-5.63)	<0.0001
Albumin (by every 1 g/dL)	0.18 (0.22-0.25)	<0.0001
Pre-ALT (by every 40 IU/L)	1.04 (0.96-1.08)	0.525
Post-ALT (by every 40 IU/L)	1.68 (1.55-1.81)	<0.0001
γ-GTP (by every 40 IU/L)	1.17 (1.08-1.27)	<0.0001
Fasting blood sugar (by every 100 mg/dL)	1.82 (1.35-2.45)	<0.0001
Pre-AFP (by every 10 ng/mL)	1.07 (1.05-1.09)	<0.0001
Post-AFP (by every 10 ng/mL)	1.08 (1.06-1.12)	<0.0001
Platelet counts (by every 10 ⁴ /μL)	0.88 (0.85-0.90)	<0.0001
Genotype		
Non-1	1	
1	2.27 (1.51-3.45)	<0.0001
Core 70 mutation		
Wild	1	
Mutant	2.79 (1.19-6.53)	0.018
ISDR		
More than 1 mutation	1	
Wild or 1 mutation	1.27 (0.87-1.85)	0.216
Virological response		
SVR	1	
Non-SVR	3.66 (2.51-5.35)	<0.0001
Multivariate analysis		
Age (by every 10 year)	2.18 (1.71-2.81)	<0.0001
Sex		
Female	1	
Male	2.66 (1.86-3.80)	<0.0001
Fibrosis stage		
F1/F2	1	
F3/F4	2.27 (1.58-3.27)	<0.0001
Degree of steatosis		
<10%	1	
≥10%	2.29 (1.49-3.50)	<0.0001
Albumin (by every 1 g/dL)	0.35 (0.23-0.55)	<0.0001
Post-ALT (by every 40 IU/L)	1.81 (1.55-2.12)	<0.0001
Post-AFP (by every 10 ng/mL)	1.06 (1.02-1.10)	0.007
Virological response		
SVR	1	
Non-SVR	1.58 (1.01-2.48)	0.044

Hazard ratios for development of hepatocellular carcinoma were calculated by the Cox proportional hazards analysis. ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase; AFP, alpha-fetoprotein; ISDR, interferon sensitivity determining region; SVR, sustained virological responder. As covariates in the multivariate stepwise Cox model, age, sex, stage of liver fibrosis, grade of histological activity, presence of hepatic steatosis, serum albumin levels, γ-GTP level, fasting blood sugar levels, platelet counts, pre-IFN ALT levels, pre-IFN AFP levels, post-IFN ALT levels, post-IFN AFP levels, and virological response were included.

decrease was found not only in SVRs, but also non-SVRs (Fig. 3A). Because post-IFN treatment ALT and AFP levels rather than pre-IFN treatment levels were




Fig. 1. Predictive values for ALT and AFP, and hazard ratios (HRs) according to post-IFN treatment ALT and AFP levels. (A) ROC curve for prediction of HCC. Area under the ROC curve, 95% CI, cutoff value, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) are shown in the bottom of the figure. (B) Spline curves of HR (solid line) and 95% CI (dotted line) for HCC development according to post-IFN treatment ALT and AFP levels. Curves were fitted using polynomial regression.

significantly associated with the development of HCC in non-SVRs, we determined the effects of changes in ALT and AFP levels by IFN therapy on hepatocarcinogenesis. Even in non-SVRs with equal or higher pre-IFN treatment ALT or AFP levels than the cutoff values, the cumulative incidence of HCC was significantly suppressed in patients whose post-IFN treatment ALT or AFP level was reduced to less than the cutoff values (Fig. 3B). In contrast, persistence of post-IFN treatment ALT or AFP levels to more than the cutoff values after IFN therapy was associated with a significantly higher incidence of HCC (Fig. 3B).

Relation Between AFP and ALT or Histological Findings. Univariate analysis using logistic regression determined factors that were associated with post-IFN treatment ALT or AFP levels (Supporting Table). Although many clinical factors were associated with post-

IFN ALT and/or AFP levels, post-IFN ALT and AFP levels were not correlated with each other ($r^2 = 0.050$). Therefore, the cumulative incidence of HCC was significantly higher in patients with higher post-IFN treatment AFP levels, even when patients were stratified by post-IFN treatment ALT levels (Fig. 4A,B).

As shown in Fig. 4C–E, the cumulative incidence of HCC development was significantly lower in patients whose post-IFN treatment AFP level was <6.0 ng/mL in all subgroups stratified by stage of fibrosis and grade of activity. Therefore, reduction in post-IFN treatment AFP levels reduces HCC risk even in patients with advanced fibrosis. Although pre-IFN treatment AFP levels correlated with the advance of histological fibrosis and grade of activity, such correlations became less significant with post-IFN treatment AFP levels (data not shown).

Platelet Counts and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) in Patients Without Advanced Fibrosis. Because a substantial amount of HCC cases developed in the patients without histologically advanced fibrosis (Fig. 4C), we characterized these individuals using platelet counts and APRI,²⁵ which are the readily available surrogate markers for liver fibrosis. We first determined the cutoff values of platelet counts and APRI for predicting HCC development by ROC analyses. Accordingly, platelet counts $<150 \times 10^3/\mu\text{L}$ and APRI >0.96 were identified as cutoff values, and the areas under the ROC curve for platelet counts and APRI were 0.715 (95% CI: 0.675–0.755) and 0.740 (95% CI: 0.701–0.779), respectively (Supporting Figure). Even in individuals without advanced fibrosis (F1 and F2 patients), the proportion of patients with platelet counts $<150 \times 10^3/\mu\text{L}$ or APRI >0.96 was significantly higher in patients with HCC than in those without HCC (platelet counts, 53.0% [35/66] versus 31.3% [387/1238], $P = 0.0002$; APRI, 53.0% [35/66] versus 26.4% [325/1229], $P < 0.0001$). Moreover, the cumulative incidence of HCC development was significantly higher in patients with platelet counts $<150 \times 10^3/\mu\text{L}$ or APRI >0.96 in the subgroups without advanced fibrosis (Supporting Figure). Therefore, patients with low platelet counts or high APRI still have a substantial risk for HCC development even though they were diagnosed with mild fibrosis by liver biopsy.

Hepatic Steatosis and Post-IFN ALT and AFP Levels in SVRs. To characterize SVRs without ALT and AFP normalization after IFN therapy, we evaluated the percentage of severe hepatic steatosis in these patients. Accordingly, the percentages of severe hepatic steatosis were significantly higher in SVRs without ALT and AFP normalization than in those with normal




Fig. 2. Cumulative incidence of HCC according to post-IFN treatment ALT and AFP levels. (A) Entire cohort stratified by post-IFN treatment ALT levels (log-rank test: $P < 0.0001$). (B) Entire cohort stratified by post-IFN treatment AFP levels (log-rank test: $P < 0.0001$). (C) Non-SVRs stratified by post-IFN treatment ALT levels (log-rank test: $P < 0.0001$). (D) Non-SVRs stratified by post-IFN treatment AFP levels (log-rank test: $P < 0.0001$). (E) SVRs stratified by post-IFN treatment ALT levels (log-rank test: $P < 0.0001$). (F) SVRs stratified by post-IFN treatment AFP levels (log-rank test: $P < 0.0001$). The number of HCC events and patients at risk at each timepoint are shown below the graphs.

ALT and AFP (ALT, 37.9% [36/95] versus 13.8% [77/557], $P < 0.0001$; AFP, 31.6% [31/98] versus 14.8% [82/554], $P < 0.0001$). Therefore, it is likely that

presence of hepatic steatosis is associated with ALT and/or AFP elevation, and it is one of the risks for HCC development even after achieving SVR.




Fig. 3. Changes in pre- and post-IFN treatment ALT and AFP levels, and their effects on HCC development. (A) Mean serum pre- (open columns) and post-IFN treatment (solid columns) ALT and AFP levels in SVRs and non-SVRs. Error bars indicate the standard error. *Paired Student *t* test. †Unpaired Student *t* test. (B) Cumulative incidence of HCC stratified by changes in pre- and post-IFN treatment ALT and AFP levels (log-rank test: $P < 0.0001$). ALT <40 → unchanged, patients with ALT <40 IU/L before IFN therapy unchanged after IFN therapy; ALT ≥40 → decreased, patients with ALT ≥40 IU/L before IFN therapy decreased to ALT <40 IU/L after IFN therapy; ALT ≥40 → unchanged, patients with ALT ≥40 IU/L before IFN therapy unchanged at ALT not <40 IU/L after IFN therapy. AFP <6.0 → unchanged, patients with AFP <6.0 ng/mL before IFN therapy unchanged at AFP <6.0 ng/mL after IFN therapy; AFP ≥6.0 → decreased, patients with AFP ≥6.0 ng/mL before IFN therapy decreased to AFP <6.0 ng/mL after IFN therapy; AFP ≥6.0 → unchanged, patients with AFP ≥6.0 ng/mL before IFN therapy unchanged at AFP ≥6.0 ng/mL after IFN therapy.

Discussion

This large-scale, long-term cohort study establishes important findings, which demonstrate a strict association between hepatocarcinogenesis and post-IFN

treatment ALT and AFP levels in patients with CHC. This association was notable in both SVR and non-SVR subgroups, and suppression of these values by IFN therapy reduced the hepatocarcinogenesis risk despite failure of HCV eradication. These data, which




Fig. 4. Relationship between AFP and ALT or histological findings. (A) The cumulative incidence of HCC stratified by post-IFN treatment AFP levels in subgroups according to the post-IFN treatment ALT (log-rank test: $P < 0.0001$ in both subgroups). (B) Cumulative incidence of HCC stratified by post-IFN treatment AFP levels in subgroups according to the histological stage of fibrosis (log-rank test: $P < 0.0001$ in both subgroups). (C) Cumulative incidence of HCC stratified by post-IFN treatment levels of AFP in subgroups according to the histological grade of activity (log-rank test: $P < 0.0001$ in both subgroups).

demonstrate the efficacy of IFN against HCC development associated with suppression of AFP, have clinically important implications for physicians.

Although there have been reports on the association between baseline pretreatment AFP levels and HCC risk,²⁶⁻³⁵ little is known regarding the effects of IFN therapy on change in post-IFN treatment AFP and its

relation to HCC risk.³⁶ Although a previous report demonstrated that a decrease in AFP levels in patients receiving IFN therapy reduced the incidence of HCC,³⁷ this study was performed in a small number of patients ($n = 382$), and cutoff values, relation to ALT, or histological findings were not determined. Our study, performed in a large well-characterized

cohort, had a greater advantage in that it allowed determination of cutoff values for post-IFN treatment ALT and AFP levels useful for predicting HCC development. Although a higher cutoff value of 20 ng/mL was used to determine the incidence of HCC in the previous study,³⁶ we propose a lower value for negatively predicting HCC. From our results, those with AFP levels ≥ 6.0 ng/mL have a substantial HCC risk, even if it is < 20 ng/mL. Therefore, post-IFN treatment AFP levels should be < 6.0 ng/mL to suppress HCC risk in patients with CHC.

It should be noted that AFP produced by HCC itself was carefully excluded in our study. Serum AFP elevation is frequently observed in patients with advanced CHC in the absence of HCC.¹⁹⁻²³ Although the precise mechanisms accounting for this observation are unknown, Hu et al.³⁸ found a correlation between AFP and measures of liver disease activity, suggesting that AFP production is enhanced in the presence of necroinflammatory injury of the liver. However, in our study post-IFN treatment ALT and AFP levels were not correlated, and the cumulative incidence of HCC was significantly higher in patients with higher post-IFN treatment AFP levels, even when patients were stratified by post-IFN treatment ALT levels. Moreover, multivariate analysis confirmed that AFP and ALT are independently associated with HCC risk. Therefore, observed elevation in AFP levels in patients with subsequent HCC development is not necessarily caused by necroinflammation of the liver. Alternatively, increased AFP levels have been reported during liver regeneration following hepatic resection and during recovery from massive hepatic necrosis,³⁹⁻⁴¹ suggesting that elevated AFP levels are a surrogate for proliferative activity of liver cells, which may cause hepatocarcinogenesis in patients with CHC.

Other possible reasons accounting for HCC risk related to AFP are the close association between AFP levels and the stage of liver fibrosis, which is consistent with a previous report.³⁵ However, we further clarified the fact that correlation between post-IFN treatment AFP levels and liver fibrosis was less notable in patients without subsequent development of HCC (data not shown). Cumulative incidence of HCC was significantly higher in patients with higher post-IFN treatment AFP levels at each stage when patients were stratified by the histological stage of fibrosis (Fig. 4). Therefore, post-IFN treatment AFP is not just a surrogate marker for liver fibrosis, and elevation of post-IFN treatment AFP as a potential risk for hepatocarcinogenesis is not only the result of advanced liver fibrosis. Conversely, suppression of post-IFN treatment

AFP levels may reduce HCC risk even in patients with advanced fibrosis.

This study has a few limitations, the first being the heterogeneity of our cohort, which included various treatment regimens with different treatment responses. However, we obtained similar results in a more uniform subgroup of HCV genotype 1b patients treated with PEG-IFN α /RBV (data not shown). The second limitation is the ethnic homogeneity of the Japanese population. Because the baseline incidence of HCC development differs among population groups, longer-term longitudinal studies in larger cohorts with various population subgroups are required to verify the generality of our results.

With the development of potent direct-acting antiviral agents combinations, IFN-free therapy is likely to be approved in the near future. This raises the question of whether posttreatment ALT and/or AFP levels will remain a significant predictor of HCC risk. Moreover, it is uncertain whether the suppressive effect of viral eradication by IFN-free regimens on hepatocarcinogenesis will be identical to that obtained by IFN-based regimens. Therefore, it is extremely interesting to prove these issues in future studies.

In conclusion, post-IFN treatment ALT and AFP levels are strictly associated with hepatocarcinogenesis risk in patients with CHC. Measurement of these values is useful for predicting future HCC risk in IFN-treated patients. Suppression of these values after IFN therapy reduces HCC risk even in patients without HCV eradication, while SVRs with increased ALT and/or AFP levels are at risk for HCC development. The present results have potentially important clinical implications for physicians and may influence their decisions regarding treatment strategy and HCC surveillance for individual patients.

References

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Semin Liver Dis* 1995;15:64-69.
2. Llover JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;362:1907-1917.
3. Parkin DM. Global cancer statistics in the year 2000. *Lancet Oncol* 2001;2:533-543.
4. Kiyosawa K, Sodeyama T, Tanaka E, Gigo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *HEPATOLOGY* 1990;12:671-675.
5. Asahina Y, Tsuchiya K, Tamaki T, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. *HEPATOLOGY* 2010;52:518-527.
6. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of IFN therapy and hepatocellular carcinoma in patients with chronic hepatitis C. *Ann Intern Med* 1998;129:94-99.
7. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of IFN therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643

- patients using statistical bias correction with proportional hazard analysis. *HEPATOLOGY* 1999;29:1124-1130.
8. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. IFN therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. *Ann Intern Med* 1999;131:174-181.
 9. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. SVR to IFN-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *HEPATOLOGY* 2007;45:579-587.
 10. Lazarevich NL. Molecular mechanisms of alpha-fetoprotein gene expression. *Biochemistry (Mosc)* 2000;65:117-133.
 11. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. *Am J Med Sci* 1992;303:157-159.
 12. Matsui H, Rimal N, Kamakura K, Uesugi S, Yamamoto H, Ikeda S, et al. Serum alpha-fetoprotein levels in healthy Japanese adults. *Acta Med Okayama* 1998;52:149-154.
 13. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. *Semin Liver Dis* 2005;25:143-154.
 14. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. *J Hepatol* 2001;34:570-575.
 15. Cedrone A, Covino M, Carurelli E, Pompili M, Lorenzelli G, Villani MR, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 Western patients. *Hepatogastroenterology* 2000;47:1654-1658.
 16. Gebo KA, Chandler G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. *HEPATOLOGY* 2002;36:S84-S92.
 17. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost utility analysis. *Am J Gastroenterol* 2003;98:679-690.
 18. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. *HEPATOLOGY* 2002;36:410-417.
 19. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alphafetoprotein levels in patients with chronic hepatitis B. *Cancer* 1989;64:2117-2120.
 20. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. *Liver* 1986;6:133-137.
 21. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am J Gastroenterol* 1998;93:2452-2456.
 22. Goldstein NS, Blue DE, Hankin R, Hunter S, Bayati N, Silverman AL, et al. Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. *Am J Clin Pathol* 1999;111:811-816.
 23. Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, et al. Clinical, virologic, and pathologic significance of elevated serum alphafetoprotein levels in patients with chronic hepatitis C. *J Clin Gastroenterol* 2001;32:240-244.
 24. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *HEPATOLOGY* 1994;19:1513-1520.
 25. Wai CT, Greenon JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *HEPATOLOGY* 2003;38:518-526.
 26. Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martinez-Tlahuel JL, et al. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. *Clin Oncol* 2007;19:197-203.
 27. Bruix J, Sherman M. Management of hepatocellular carcinoma. *HEPATOLOGY* 2005;42:1208-1236.
 28. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med* 1991;325:675-680.
 29. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 1993;328:1797-1801.
 30. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *HEPATOLOGY* 1994;19:61-66.
 31. Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. *HEPATOLOGY* 1996;23:1112-1118.
 32. Sangiovanni A, Colombo E, Radaelli F, Bortoli A, Bovo G, Casiraghi MA, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. *Am J Gastroenterol* 2001;96:1575-1580.
 33. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. *J Hepatol* 2006;44:1089-1097.
 34. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, et al. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. *J Viral Hepatol* 2008;15:179-187.
 35. Tateyama M, Yatsuhashi H, Taura N, Moroyoshi Y, Nagaoka S, Yanagi K, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. *J Gastroenterol* 2010;46:92-100.
 36. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. *J Hepatol* 2005;43:434-441.
 37. Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. *J Gastroenterol* 2012;47:444-451.
 38. Hu K-Q, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. *Am J Gastroenterol* 2004;99:860-865.
 39. Watanabe A, Shiota T, Hayashi S, Nagashima H. Serum alphafetoprotein in fulminant hepatitis and hepatic regeneration following partial hepatectomy. *Biochem Med* 1984;32:132-137.
 40. Yang SS, Cheng KS, Lai YC, Wu CH, Chen TK, Lee CL, Chen DS. Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. *J Gastroenterol* 2002;37:626-632.
 41. Horn KD, Wax P, Schneider SM, Martin TG, Nine JS, Moraca MA, et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. *Am J Clin Pathol* 1999;112:351-357.

Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C

Yasuhiro Asahina · Kaoru Tsuchiya · Takashi Nishimura · Masaru Muraoka · Yuichiro Suzuki · Nobuharu Tamaki · Yutaka Yasui · Takanori Hosokawa · Ken Ueda · Hiroyuki Nakanishi · Jun Itakura · Yuka Takahashi · Masayuki Kurosaki · Nobuyuki Enomoto · Mina Nakagawa · Sei Kakinuma · Mamoru Watanabe · Namiki Izumi

Received: 11 April 2013 / Accepted: 4 July 2013
© Springer Japan 2013

Abstract

Background We aimed to clarify the association between single nucleotide polymorphism (SNP) located near *interleukin 28B* and hepatocellular carcinoma (HCC).

Methods A cohort comprising 792 patients treated with interferon for chronic hepatitis C was investigated. SNPs at rs8099917 and rs12979860 were determined. Cumulative incidence and HCC risk were analyzed by Kaplan–Meier and Cox proportional hazard analyses for a mean follow-up period of 4.9 years. Fibrosis progression rate (FPR) was determined in these patients with a known time of infection ($n = 294$).

Results Cumulative HCC incidence was significantly higher in rs8099917 nonTT (minor homozygote or heterozygote) patients than in rs8099917 TT (major

homozygote) patients (20.8 vs. 10.5 % over 10 years, logrank test, $p = 0.002$). This difference was notable in patients infected with genotype 1 and those treated with pegylated interferon and ribavirin. Among nonSVRs, interferon had a limited effect in suppressing alanine aminotransferase (ALT) and/or α -fetoprotein (AFP) levels in nonTT patients. The suppression of these values after interferon therapy was associated with a lower incidence of HCC. FPR were similar in TT and nonTT patients.

Conclusions rs8099917 nonTT is related to higher HCC development in patients with HCV genotype 1 and those treated with pegylated interferon and ribavirin. Higher HCC incidence observed in nonTT patients partly results from the limited suppression of ALT and/or AFP by interferon in these patients.

Keywords Hepatocarcinogenesis · Fibrosis · Interferon · Alanine aminotransferase · α -Fetoprotein

Electronic supplementary material The online version of this article (doi:10.1007/s00535-013-0858-2) contains supplementary material, which is available to authorized users.

Y. Asahina · K. Tsuchiya · T. Nishimura · M. Muraoka · Y. Suzuki · N. Tamaki · Y. Yasui · T. Hosokawa · K. Ueda · H. Nakanishi · J. Itakura · Y. Takahashi · M. Kurosaki · N. Izumi

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan

Y. Asahina (✉) · M. Nakagawa · S. Kakinuma · M. Watanabe
Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
e-mail: asahina.gast@tmd.ac.jp

Y. Asahina · S. Kakinuma
Department of Liver Disease Control, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

T. Nishimura
Department of Gastroenterology, Faculty of Medicine, Shiga University of Medical Science, Setatsukinowa-cho, Otsu-shi, Shiga 520-2192, Japan

M. Muraoka · Y. Suzuki · N. Enomoto
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110 Shimogato, Chuo-shi, Yamanashi 409-3898, Japan

Introduction

Hepatitis C virus (HCV) infection is one of the major causes of chronic hepatitis, which progresses to hepatocellular carcinoma (HCC) in many patients [1]. In the last two decades, interferon (IFN) therapy has been used to treat chronic hepatitis C (CH-C) with the goal of altering its natural progression. Although HCV eradication with IFN therapy in CH-C patients reportedly prevents HCC development [2–4], factors responsible for HCC development in IFN-treated patients are difficult to determine because of the prolonged clinical course of CH-C.

Recent studies demonstrated that single nucleotide polymorphisms (SNPs) near *interleukin (IL) 28B* were strongly associated with the virological response to pegylated IFN α (PEG-IFN α) and ribavirin (RBV) combination therapy [5–7]. However, it remains unclear if the SNPs near *IL28B* are associated with further consequences of CH-C, such as HCC and liver fibrosis, in IFN-treated patients because of the paucity of adequate cohort studies. To address the important question of whether SNPs near *IL28B* are associated with the development of HCC, we analyzed the influence of this polymorphism on HCC risk in a large-scale, long-term cohort of IFN-treated patients.

Methods

Patients

Patients chronically infected with HCV who had histologically proven chronic hepatitis or cirrhosis and had undergone IFN treatment between 1992 and 2010 were enrolled in the original cohort [8]. In this cohort comprising 1,818 patients, a subgroup of 792 patients who were available for genotyping of the SNPs near *IL28B* (rs8099917 and rs12979860) was assessed in the present study. Patients were excluded from the original cohort if they had a history of HCC at the time of liver biopsy, autoimmune hepatitis, primary biliary cirrhosis, excessive alcohol consumption (≥ 50 g/day), hepatitis B surface antigen, or anti-human immunodeficiency virus antibody. HCC was definitively ruled out by ultrasonography, dynamic computed tomography (CT), and/or magnetic resonance imaging (MRI) on enrollment. Written informed consent was obtained from all patients, and the Ethical Committee of Musashino Red Cross Hospital approved this study, which was conducted in accordance with the Declaration of Helsinki.

Genotyping for SNPs near *IL28B* (rs8099917 and rs12979860)

Genetic polymorphisms in tagged SNPs located near *IL28B* (rs8099917 and rs12979860) were determined by direct

sequencing of PCR-amplified DNA, as reported previously [9].

Histological evaluation

Laparoscopic or ultrasound-guided liver biopsy was undertaken using 13-gauge or 15-gauge needles, respectively. The median length of specimens was 18 mm (range 11–40 mm), and the median number of portal tracts was 18 (range 9–34). Fibrosis stage and grade of inflammatory activity were scored by two pathologists according to Desmet et al.'s classification [10]. In case of interobserver disagreement in histological staging or grading, the diagnosis was confirmed by consensus.

IFN therapy and definitions of response to IFN therapy

All patients had chronic HCV infection at liver biopsy, which was confirmed by the presence of HCV-RNA in serum. All IFN therapies were initiated within 48 weeks after liver biopsy. Of 792 patients, 71 patients received IFN α or IFN β monotherapy for 24 weeks, 54 received IFN α /RBV combination therapy for 24 weeks, 118 received PEG-IFN α monotherapy for 48 weeks, and 549 received PEG-IFN α /RBV combination therapy for 48–72 weeks.

Patients negative for serum HCV-RNA 24 weeks after IFN therapy completion were defined as sustained virological responders (SVRs). Patients who remained positive for HCV-RNA 24 weeks after therapy completion were defined as nonSVRs. HCV-RNA was determined by the qualitative Amplicor or TaqMan HCV assay (Roche Molecular Diagnostics, Tokyo, Japan).

Data collection and patient follow up

At primary liver biopsy, patient characteristics and biochemical, hematological, virological, and histological data were evaluated. Age at primary liver biopsy was determined. Patients were examined for HCC by abdominal ultrasonography, dynamic computed tomography, and/or magnetic resonance imaging every 3–6 months. Serum alanine aminotransferase (ALT) and α -fetoprotein (AFP) levels were measured every 1–6 months. Surveillance protocols were in accordance with the standard of care in Japan. If HCC was suspected on the basis of the screening examination, additional procedures (e.g., dynamic CT, dynamic MRI, CT during hepatic arteriography, CT during arterial portography, contrast-enhanced ultrasonography, and tumor biopsy) were used to confirm the diagnosis. HCC diagnosis was confirmed by needle biopsy, histology of surgically resected specimens, or characteristic radiological findings. To evaluate the effect of changes in serum ALT and AFP levels during IFN therapy on

hepatocarcinogenesis, mean integration values of ALT and AFP in each patient were calculated before and after IFN therapy. In patients who developed HCC, data obtained more than 1 year prior to HCC development were used to exclude AFP elevation caused by HCC itself.

Follow-up was between the date of primary liver biopsy and HCC development or the last medical attendance until June 2011. The mean follow-up period was 4.9 years (range 1.0–18.6 years).

Determination of changes in fibrosis stage over time

Changes in fibrosis stage over time were determined in patients who showed evidence of a single blood transfusion as a known time of HCV infection. Two hundred ninety-four patients had a single blood transfusion before 1992, indicating the known time of HCV infection (rs8099917 TT, $n = 217$; rs8099917 nonTT, $n = 77$). In this subgroup, 221 (75.2 %) patients were infected with HCV genotype 1. Annual fibrosis progression rate (FPR) was calculated as the fibrosis stage at liver biopsy divided by HCV infection duration, which was determined by the period between blood transfusion and liver biopsy (mean duration, 35.1 years; range 12.0–60.0 years).

Statistical analyses

Categorical data were compared by Chi-square or Fisher's exact tests. Continuous variable distributions were analyzed with Student's *t*- or Mann–Whitney *U* test. All tests of significance were two-tailed. $p < 0.05$ was considered significant. The cumulative incidence curve was determined by the Kaplan–Meier method, and differences between groups were assessed using the logrank test. Factors associated with HCC risk were determined by the Cox proportional hazard model. As covariates in the multivariate stepwise Cox model, age, sex, stage of liver fibrosis, pre- and post-IFN treatment ALT and AFP levels, virological response, and *IL28B* genotype were included. HCC development was the dependent variable. Time zero was defined as the time of primary liver biopsy. The proportional assumption was supported by $\log[-\log(\text{survival})]$ vs. $\log(\text{time})$ plots, which showed parallel lines. Statistical analyses were performed using the Statistical Package for the Social Sciences software (version 18.0) (SPSS Inc., Chicago, IL, USA).

Results

Patient characteristics and the SNPs near *IL28B*

Patient characteristics are demonstrated in Table 1. Frequency of the rs8099917 genotype was as follows: major

homozygote (TT), 74.2 % (588/792); heterozygote (TG), 24.2 % (192/792); and minor homozygote (GG), 1.5 % (12/792). Genotypic distribution of this SNP was consistent with that in a recent report on Japanese patients [5]. The frequency of the rs12979860 genotype was as follows: major homozygote (TT), 73.4 % (581/792); heterozygote (TG), 25.1 % (199/792); and minor homozygote (GG), 1.5 % (12/792). The genotypic discrepancy between rs8099917 and rs12979860 was found only in seven patients. Therefore, the genotypes of the two SNPs (rs8099917 and rs12979860) were 99.1 % identical. All seven patients had a major homozygote (TT) in rs8099917 but a heterozygote (CT) in rs12979860, and HCC developed in one of seven patients at 2.2 years after initiation of the follow-up.

Response to IFN therapy

The final responses to IFN therapy (SVR or nonSVR) were determined in all patients. SVR rate was significantly higher in TT patients than in nonTT patients (58.3 vs. 27.9 %, $p < 0.001$) (Table 1). SVR rates for each therapeutic regimen in TT and nonTT patients, respectively, were as follows: IFN monotherapy, 35.7 % (20/56) vs. 26.7 % (4/15), $p = 0.759$; IFN α /RBV combination therapy, 46.3 % (19/41) vs. 15.4 % (2/13), $p = 0.057$; PEG-IFN α monotherapy, 63.2 % (55/87) vs. 35.5 % (11/31), $p = 0.008$; PEG-IFN α /RBV combination therapy, 61.6 % (249/404) vs. 27.6 % (40/145), $p < 0.001$.

Factors associated with the SNPs near *IL28B*

NonTT patients were significantly associated with higher γ -glutamyl transpeptidase levels, lower low-density lipoprotein cholesterol levels, higher hepatic steatosis frequency, glutamine or histidine mutations at amino acid position 70 (70QH) in the HCV core region, and one or no mutation in the IFN sensitivity-determining region in the HCV nonstructural 5A gene (Table 1).

Cumulative incidence of HCC according to the SNPs near *IL28B*

During follow-up, 53 patients developed HCC (Table 1). At 3, 5, and 10 years, the overall cumulative incidence of HCC was 3.4, 7.4, and 13.1 %, respectively. The cumulative incidence of HCC at 5 and 10 years was significantly higher in nonTT patients than in TT patients (13.0 and 20.8 % vs. 5.4 and 10.5 %, respectively; logrank test, $p = 0.002$) (Fig. 1a). Among SVRs, no significant difference was found in the cumulative HCC incidence between TT and nonTT patients (Fig. 1b). However, the cumulative incidence of HCC among nonSVRs was significantly

Table 1 Characteristics of patients and comparison between the SNPs near *IL28B*

Characteristics	Total	rs8099917 TT	rs8099917 nonTT	<i>p</i> value*
Patients, <i>n</i>	792	588	204	
Sex, <i>n</i> (%)				0.329 [†]
Male	310 (39.1)	236 (40.1)	74 (36.3)	
Female	482 (60.9)	352 (59.9)	130 (63.7)	
Age (SD), year	58.6 (10.7)	58.5 (10.6)	58.8 (11.0)	0.684 [‡]
BMI (SD), kg/m ²	22.8 (3.2)	22.9 (3.2)	22.7 (3.3)	0.382 [‡]
Fibrosis stage, <i>n</i> (%)				0.751 [†]
F1/2	612 (77.3)	456 (77.6)	156 (76.5)	
F3/4	180 (22.7)	132 (22.4)	48 (23.5)	
%Severe steatosis (≥10%)	25.3	21.4	35.4	<0.001 [†]
ALT level (SD), IU/L	63.4 (52.5)	64.9 (50.1)	59.0 (42.9)	0.170 [‡]
γ-GTP level (SD), IU/L	45.9 (45.3)	41.5 (43.5)	58.3 (47.9)	<0.001 [†]
LDL-C level (SD), mg/dL	99.8 (26.8)	102.0 (26.6)	93.6 (26.8)	0.034 [‡]
AFP level (SD), ng/mL	10.3 (26.7)	8.24 (12.2)	16.4 (47.9)	<0.001 [†]
Platelet counts (SD), ×10 ³ /μL	164 (52)	163 (51)	167 (56)	0.422 [‡]
HCV load (SD), KIU/mL	1550 (1465)	1612 (1465)	1392 (1457)	0.107 [‡]
HCV genotype, <i>n</i> (%) ^a				0.065 [†]
1a	8 (1.0)	5 (0.9)	3 (1.5)	
1b	588 (74.8)	422 (72.4)	166 (81.7)	
2a	118 (15.0)	96 (16.5)	22 (10.8)	
2b	63 (8.0)	52 (8.9)	11 (5.4)	
Others	9 (1.1)	8 (1.4)	1 (0.5)	
%Core 70 a.a. mutation ^b	34.5	26.2	57.1	<0.001 [†]
%ISDR wild or 1 mutation ^c	67.4	64.0	76.1	0.005 [†]
Duration (SD), year	4.9 (3.0)	5.0 (3.1)	4.8 (2.8)	0.480 [‡]
IFN regimen, <i>n</i> (%)				0.798 [†]
IFN mono	71 (9.0)	56 (9.5)	15 (7.4)	
IFN + RBV	54 (6.8)	41 (7.0)	13 (6.4)	
PEG-IFN mono	118 (14.9)	87 (14.8)	31 (15.2)	
PEG-IFN + RBV	549 (69.3)	404 (68.7)	145 (71.1)	
SVR, <i>n</i> (%)	400 (50.5)	343 (58.3)	57 (27.9)	<0.001 [†]
HCC, <i>n</i> (%)	53 (6.7)	30 (5.1)	23 (11.3)	0.002 [†]

* Comparison between *IL28B* major and minor genotypes

[†] Chi-square test

[‡] Student's *t*-test

^a HCV genotype was determined in 786 patients (*n*: *IL28B* major = 583, minor = 203)

^b HCV core mutation was determined in 313 patients with genotype 1b

^c ISDR was determined in 585 patients with genotype 1b


higher in nonTT patients than in TT patients (15.5, and 24.8 vs. 7.2 %, and 15.4 % at 5, and 10 years, respectively; logrank test, *p* = 0.016) (Fig. 1c). Similar results were obtained when the rs12979860 genotype was used as a reference. That is, the cumulative incidences of HCC at 5 and 10 years in overall patients were 13.1 and 20.5 % in nonCC patients and 5.2 and 10.4 % in CC patients (logrank test, *p* = 0.001); those in SVRs were 3.8 and 4.9 % in CC patients and 4.9 and 4.9 % in nonCC patients; and those in nonSVRs were 15.9 and 25.1 % in nonCC patients and 6.8 and 15.0 % in CC patients (logrank test, *p* = 0.008).

Ten subjects [rs8099917 TT, *n* = 9; nonTT, *n* = 1; SVR, *n* = 8; nonSVR, *n* = 2; mean follow-up period = 4.3 years (range 1.1–8.3 years)] were lost to follow-up during the last 2 years. These patients were censored from the cumulative incidence analyses at the time of the last visit.

In this study cohort, only three (one TT, *n* = 1; nonTT, *n* = 2) patients died during follow-up, and no patient underwent liver transplantation. These deaths were HCC-related. Therefore, it is unlikely that competing risks would have affected our results regarding differences in HCC incidence between TT and nonTT patients.

Because the SNPs near *IL28B* affects treatment responses particularly in patients infected with HCV genotype 1 and/or those treated with PEG-IFN α /RBV combination therapy, the cumulative incidences of HCC were analyzed in a subgroup of the patients. In patients infected with HCV genotype 1 (*n* = 596), the cumulative incidence of HCC was significantly higher in nonTT patients than in TT patients (15.2 and 24.9 % vs. 6.4 and 10.5 % at 5, and 10 years, respectively; logrank test, *p* = 0.001) (Fig. 1d). In patients treated with PEG-IFN α /RBV combination therapy (*n* = 549), the cumulative incidence of HCC was also

Fig. 1 Cumulative incidence of HCC according to genetic variation near *IL28B*. **a** Data for the entire patient group. Logrank test: $p = 0.002$. **b** Data for SVRs. Logrank test: $p = 0.775$. **c** Data for nonSVRs. Logrank test: $p = 0.016$. **d** Data for patients with HCV genotype 1. Logrank test: $p = 0.001$. **e** Data for patients who were treated with PEG-IFN α /RBV combination therapy. Logrank test: $p < 0.001$. **f** Data for patients with HCV genotype 1 who were treated with PEG-IFN α /RBV combination therapy. Logrank test: $p < 0.001$



significantly higher in nonTT patients than in TT patients (17.9, and 22.7 vs. 2.6, and 3.6 % at 5, and 9 years, respectively; logrank test, $p < 0.001$) (Fig. 1e). Particularly, in patients infected with HCV genotype 1 who were treated with PEG-IFN α /RBV ($n = 443$), the cumulative incidence of HCC was significantly higher in nonTT patients than in

TT patients (19.5, and 24.5 vs. 2.2, and 3.2 % at 5, and 9 years, respectively; logrank test, $p < 0.001$) (Fig. 1f). Among patients infected with HCV genotype non-1 or those treated with other than PEG-IFN α /RBV therapy, no significant difference was found in the cumulative HCC incidence between TT and nonTT patients.

Influence of the SNPs near *IL28B* on progression of fibrosis over time

Among the 294 patients with evidence of a single blood transfusion, the annual FPR was similar between TT and nonTT patients ($p = 0.758$, Fig. 2). No difference was found in age at blood transfusion (26.0 [SD, 9.7] years old vs. 26.5 [SD, 9.6] years old, $p = 0.658$) and duration of HCV infection (34.7 [10.0] years vs. 36.1 [9.9] years, $p = 0.291$) between TT and nonTT patients.

Mean ALT and AFP levels after IFN therapy according to the SNPs near *IL28B*

Because we recently reported that post-IFN treatment ALT and AFP levels are significantly associated with hepatocarcinogenesis [8], the influence of ALT and AFP levels after IFN treatment was determined in TT and nonTT patients to address possible reasons associated with higher HCC development observed in nonSVRs with rs8099917 nonTT. Overall, mean serum ALT and AFP levels were reduced after IFN therapy. However, the reduction observed in mean ALT and AFP levels after IFN therapy was less in nonTT patients than in TT patients among nonSVRs (Fig. 3). The cutoff values of ALT and AFP after IFN treatment for predicting patients without HCC developments were determined as ALT <40 IU/L and AFP <6.0 ng/mL by the receiver–operator characteristics curves analysis in the original cohort [8]. The cumulative incidence of HCC development in nonSVRs was less in patients whose post-IFN ALT or AFP levels were below these cutoff values (Fig. 4a, b). Even in patients whose ALT \geq 40 IU/L or AFP \geq 6.0 ng/mL before IFN therapy, patients with a reduction of ALT <40 IU/L or AFP <6.0 ng/mL after IFN therapy showed significantly lower cumulative development of HCC than those without




Fig. 2 Changes in fibrosis staging over time. Analysis in patients who showed evidence of a single blood transfusion as a known time of HCV infection ($n = 292$)

reduction in both TT and nonTT subgroups (Fig. 4c–f). However, the proportion of patients with reduction of ALT <40 IU/L or AFP <6.0 ng/mL after IFN therapy in nonSVRs was significantly smaller in nonTT patients than TT patients (Fig. 5).

As reported in the recent study [8], the persistence of post-IFN treatment ALT or AFP levels to more than the cutoff values after IFN therapy was associated with a significantly higher incidence of HCC in both SVRs and nonSVRs (Supplementary Figure). In contrast, even in nonSVRs with an equal or higher pre-IFN treatment ALT or AFP level than the cutoff values, the cumulative incidence of HCC was significantly suppressed in patients whose post-IFN treatment ALT or AFP level was reduced to less than the cutoff values (Supplementary Figure).


Influence of the SNPs near *IL28B* on HCC risk

Univariate analysis demonstrated that nonTT was one of the factors that increased the risk ratio for HCC development (Table 2). In the multivariate Cox model, age, sex, stage of fibrosis, pre-IFN treatment AFP level, post-IFN treatment ALT and AFP levels were independently associated with HCC risk among covariates including age, sex, stage of fibrosis, pre- and post-IFN treatment ALT and AFP levels, virological response and the SNPs near *IL28B* (Table 3). In patients infected with HCV genotype 1 who were treated with PEG-IFN α /RBV combination therapy, the SNPs near *IL28B* as well as age, sex, post-IFN treatment ALT level and pre-IFN treatment AFP level were identified as independent factors associated with the development of HCC among covariates including age, sex, stage of liver fibrosis, pre- and post-IFN treatment ALT and AFP levels, and virological response (Table 4). Although pre-IFN treatment AFP levels were significantly higher in patients with nonTT (Table 1; Fig. 3), our results for the multivariate analysis in this subgroup suggests that higher HCC incidence in nonTT patients is not fully explained by higher pre-IFN treatment AFP levels.

Discussion

By analyzing a large-scale, long-term cohort, we demonstrated that rs8099917 nonTT is significantly associated with HCC development particularly in patients infected with HCV genotype 1 who were treated with PEG-IFN α /RBV combination therapy. The possible relationship between the SNPs near *IL28B* and the risk of HCC development is controversial [11–13] mainly because of the lack of a longitudinal cohort study such as ours. Another possible reason for this controversy is the influence of antiviral therapy because the SNPs near *IL28B* are


Fig. 3 Mean integration ALT and AFP values before and after interferon therapy in rs8099917 TT and nonTT patients. Error bars indicate the standard error. *p* values were determined by unpaired Student's *t* test



strongly associated with the antiviral response. Recent cross-sectional studies in patients without IFN treatment could not ascertain the relationship between the SNPs near *IL28B* and HCV-related HCC [12, 13]. From this viewpoint, our cohort is unique in that it includes only IFN-

treated patients. In the Kaplan-Meier analyses, significantly higher incidence of HCC in nonTT was observed in patients infected with HCV genotype 1 and/or those treated with PEG-IFN α /RBV combination therapy, whereas it was not in patients infected with HCV genotype non-1 and

Fig. 4 Cumulative incidence of HCC stratified by mean integration values of post-IFN ALT and AFP levels. **a** Stratified by post-IFN treatment levels of ALT in all patients. Logrank test: $p < 0.001$. **b** Stratified by post-IFN treatment levels of AFP in all patients. Logrank test: $p < 0.001$. **c** According to changes in mean ALT levels before and after interferon therapy in patients with rs8099917 TT. Logrank test: $p < 0.001$. **d** According to changes in mean AFP levels before and after interferon therapy in patients with rs8099917 TT. Logrank test: $p = 0.040$. **e** According to changes in mean ALT levels before and after interferon therapy in patients with rs8099917 nonTT. Logrank test: $p < 0.001$. **f** According to changes in mean AFP levels before and after interferon therapy in patients with rs8099917 nonTT. Logrank test: $p < 0.001$



those treated other than PEG-IFN α /RBV. Moreover, our multivariate analyses demonstrated that an independent association between rs8099917 nonTT and HCC development was only found in patients infected with HCV genotype 1 who were treated with PEG-IFN α /RBV combination therapy. Because the SNPs near *IL28B* affects antiviral response particularly in patients infected with HCV genotype 1 and/or those treated with PEG-IFN α /RBV therapy, impact of the SNPs near *IL28B* on HCC risk may be indirect and is largely influenced by treatment effect.

Because a significantly higher incidence of HCC in nonTT patients was observed even in nonSVRs, higher HCC risk related to nonTT was not fully explained by the poor virological response rates observed in nonTT patients. Although we have reported that higher post-IFN treatment ALT and AFP levels were significantly associated with the risk of HCC [8], the relationship between *IL28B* SNPs and post-IFN treatment ALT and AFP levels has not yet been elucidated. Hence, to further address the higher HCC risk in nonTT patients, we directed our study at post-IFN